Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
MINIRIN is a nasal spray formulation of desmopressin, a synthetic vasopressin analog used to treat central diabetes insipidus and nocturnal enuresis. The drug works by replacing or supplementing endogenous antidiuretic hormone (ADH) to restore normal fluid balance and urine output. It is administered intranasally for rapid absorption and patient convenience.
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting defensive commercial strategy and potential team right-sizing as exclusivity erosion accelerates.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
Study of Minirin Melt® in Adult Patients With Nocturia
A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia
A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
Worked on MINIRIN at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MINIRIN offers stability in a niche specialty market but limited growth upside as the product approaches loss of exclusivity. Career advancement is better pursued on higher-growth pipeline assets or emerging franchise therapies within Ferring Pharmaceuticals.